skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Cardiovascular effects of soman. Annual report Number 2, June 1, 1983-May 31, 1984

Technical Report ·
OSTI ID:7226885

Intravenous (i.v.) injection of soman in the rat produced a rapid and dose-related increase in blood pressure. The dose-response curve was very steep, threshold responses occurring after i.v. injection of 10 ug/kg, and maximum increases of about 50 mmHg occurring after 40 ug/kg. Heart rate also generally increased. An increase in blood pressure also followed injection of soman subcutaneously (s.c.), intramuscularly (i.m.) intraperitoneally (i.p.) and into the cerebral ventricles, although the onset was slower and higher doses were required. The magnitude of the pressor response was correlated with the degree of acetylcholinesterase (AChE) activity in the cortex, hypothalamus and brainstem, but not in the striatum. The pressor response was aborted or prevented by atropine, but not by methylatropine. It also was prevented by phenoxybenzamine. Atropine increased survival following an LD50 dose of soman; phenoxybenzamine prevented the pressor response but did not alter survival rate. Sarin and diisopropylfluorophosphate (DFP) also produced a pressor response following i.v. administration. The effect of sarin was similar to that of soman, although sarin was about 50% less potent. The pressor response to DFP was about 1/20th as potent as soman.

Research Organization:
University of Medicine and Dentistry of New Jersey, Newark, NJ (United States)
OSTI ID:
7226885
Report Number(s):
AD-B-088953/5/XAB; CNN: DAMD17-82-C-2154
Country of Publication:
United States
Language:
English